VERAXA Biotech (NASDAQ: VRXA) has released new in vitro proof-of-concept data for its BiTAC-ADC technology platform, demonstrating the ability to selectively target breast cancer cells while sparing healthy tissue. The data, announced today, show that BiTAC-ADCs achieved dose-dependent killing of 3D tumor cell spheroids, a model that closely mimics solid tumor architecture. The platform uses separately delivered, systemically inactive precursor components that only combine into active therapeutic agents within the tumor microenvironment, thereby minimizing off-target toxicity.
According to the company, these findings further validate the BiTAC-ADC platform and complement its existing BiTAC-TCE technology. Together, they provide VERAXA with two differentiated approaches for treating multiple solid tumor indications. The company plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego, scheduled for June 22–25, 2026. Management views the data as a critical step toward advancing the platform toward clinical development.
The full press release is available at https://ibn.fm/QiPhH. VERAXA Biotech AG, founded on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), focuses on developing antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs. The company applies rigorous quality-by-design principles to its pipeline.
The announcement underscores the growing interest in conditional activation technologies that aim to improve the therapeutic index of potent cancer drugs. By restricting drug activity to tumor sites, BiTAC-ADCs could reduce systemic side effects and enable the use of more powerful payloads. The ability to distinguish between cancer and healthy cells in vitro suggests potential for broader application across solid tumor types.
VERAXA’s management intends to leverage these data to initiate partnership discussions at BIO 2026. The company’s newsroom provides ongoing updates at https://ibn.fm/VRXA. Forward-looking statements in this article involve risks and uncertainties, as detailed in the company’s SEC filings, including its Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. These factors may cause actual results to differ materially from those projected. Investors should not place undue reliance on forward-looking statements, which are based on information available as of the date of this article.
